Pharmaceutical firm Strides Arcolab holds a 12% stake in the biosimilar developer after investing $9m in 2014.
Oncobiologics, a US-based biosimilar developer that counts pharmaceutical company Strides Arcolab among its investors, has filed for a $115m initial public offering on Nasdaq.
Founded in 2011, Oncobiologics is working on complex biosimilar therapeutics for immunology and oncology.
The IPO proceeds will be used to advance two product candidates through phase 3 clinical trials and two more into phase 1 trials. Additional capital will fund research and development activities, including the completion of the company’s R&D facility.